Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROSTVAC + Flutamide in Non-Metastatic Prostate Cancer
NCT00450463Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Feb 2007
- Primary completion
- Apr 2017
- Modality
- Viral Vectors, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of rilimogene galvacirepvec in prostate cancer (PCa), sponsored by National Cancer Institute. Started Feb 2007; status: completed.
02
Drugs
rilimogene galvacirepvec
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00450463.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00450463.